I guess all the Top 20 shareholders have to stay on message and...

I guess all the Top 20 shareholders have to stay on message and pump this abysmal failure of a biotech ? lol


Fact: @Gumnut70 has banged on ad nauseum for years of how good the science supposedly is (akin the the old CEO in that regard)


Fact: There has not been one single DEP license deal (go nowhere research agreements don't count as a license deal) in all the years of the company touting they were in commercial in confidence discussions with several potential partners as advised in 25 Nov 2021 ASX announcement (below). Let's face it, not even the current supposed partners have signed one at this stage ?





.... and I am not confused about the science and commercial successes - they go hand in hand and it is delusional to think otherwise. IF the science was as good as @Gumnut70 and others on here continually claim after multiple phase 2 trial results have now been released then big pharma would be signing DEP license deals or making a takeover offer while we are at record low share prices .... they simply are not so why is that if the science is supposedly so good ?


As for your defense of the new CEO .... you seem to forget that the Medicxi deal has been in the works for more than 12 months prior to her beginning her tenure and yet she executed that deal in <6 months (years short of the ongoing DEP negotiations) so why can't she get a DEP deal signed that has (as we all know) been in negotiations for years - IMHO big pharma don't want it (or not for the price Starpharma want for it) as the science is not as good as you all continually claim or they would have secured it by now ... simples


Watch out for the 'difficult decisions' and 'trade offs' eluded to in the recent Quarterly Report on 30 April 2024 in the upcoming webinar if it happens - just sayin'